CPHI Milan: Beyond generics, how Indian pharma is rewriting its global playbookAt CPHI Milan, Indian pharma players are looking beyond traditional exports, using partnerships, licensing, CDMO, and differentiated produc...
08 Oct, 2026, 04.29 PM IST
Aurobindo Pharma launches generic Advair Diskus for asthma and COPD in USLannett Company, part of Aurobindo Pharma, has launched generic Advair Diskus in the US, making it the first complex inhalation product fro...
31 Aug, 2026, 06.18 PM IST
Aurobindo Pharma gains over 3% as subsidiary launches generic Advair Diskus in US; stock up 41% YTDAurobindo Pharma shares rose sharply after its subsidiary Lannett Company launched the generic equivalent of Advair Diskus in the US. The i...
31 Aug, 2026, 04.12 PM IST
Cipla faces revenue and margin pressure ahead of Revlimid patent expiryCipla faces revenue and margin pressure due to the upcoming Revlimid patent expiry, leading to underperformance and analyst downgrades. Mar...
04 Jul, 2025, 06.11 AM IST
Fundamental Radar | Cipla upgraded to “buy” on 5 major growth tailwinds: Motilal OswalCipla recorded an 8% growth in sales on the back of the launch of the generic version of Revlimid and gained market share in lanreotide, al...
25 Sep, 2023, 09.43 AM IST
Cipla stocks dive to 7-month low; here’s why bears are ruling the counterIf they are minor in nature, then it is unlikely to hurt sales from the unit. However, if the regulator found major deviations from good ma...
20 Feb, 2023, 11.29 AM IST
Cipla submits application with USFDA for generic version of asthma drugDrug major Cipla on Monday said it has submitted an application with the US health regulator for a generic version of GSK's Advair Diskus, ...
18 May, 2020, 10.51 AM IST
Cipla jumps 8% on completing Phase-3 clinical study of asthma drugThe generic would be used for treatment of asthma and chronic obstructive pulmonary disease.
03 Apr, 2020, 03.58 PM IST
Cipla’s India revenue grows 13%: Key Q3 takeawaysTotal revenue increased 9.06 per cent to Rs 4,371 crore during the quarter under review.
05 Feb, 2020, 09.02 PM IST
The colour purple that has left drug makers like Dr Reddy's Laboratories paleThe reference here has nothing to do with the Pulitzer-winning book of Alice Walker, but the actual colour that has pushed big pharma to pu...
14 Nov, 2015, 02.53 PM IST
Cipla slips as rival Mylan launches generic Seretide in UK's $400-mn anti-asthma drug marketShares of Cipla fell nearly 3 per cent intraday after rivals Mylan launched first generic version of anti-asthma drug Seretide.
09 Jun, 2015, 06.32 PM IST
Lupin ties up with Poland-based firm for generic asthama drugLupin has set up a dedicated centre of excellence for inhalation research in Florida after having hired top notch inhalation scientists las...
17 Feb, 2015, 03.46 PM IST
Cipla launches combination inhalers in Germany and Sweeden; stocks touch all time high, may trigger reratingThe maiden launch increases the possibility and visibility of subsequent launches of the company’s inhalers in other countries.
04 Sep, 2014, 03.32 AM IST
Brokerages raise Cipla's target price post inhaler launchAnalysts at Emkay Global Financial Services are of the view that the launch will have a strong positive impact on the company’s margins.
02 Sep, 2014, 11.44 AM IST
- Lupin to file new drug application for GSK’s $8 bn blockbuster inhaler Advair
Mumbai-based drug maker Lupin Pharma will file an Abbreviated New Drug Application for GSK’s $8-billion dry powder inhaler Advair, said Vin...
26 Jul, 2012, 11.49 AM IST
- Brokers' Call: ONGC, DRL, Cipla and Coal India
We have compiled stock views and recommendations from various agencies on ONGC, Dr Reddy's, Cipla and Coal India.
06 Mar, 2012, 10.36 AM IST
- RBS recommends a 'Buy' rating on Cipla
RBS has recommended a 'Buy' rating on Cipla with a target price of 360.
06 Mar, 2012, 05.23 AM IST